Defeating kinases that promote tumorigenesis through non-catalytic functions with PROTACs - PIM kinase as an example.
作者信息
Torres-Ayuso Pedro, Brognard John
机构信息
Department of Cancer and Cellular Biology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
出版信息
Expert Opin Ther Targets. 2025 Apr-May;29(4-5):189-191. doi: 10.1080/14728222.2025.2500418. Epub 2025 May 4.
Abstract
摘要
相似文献
1
Defeating kinases that promote tumorigenesis through non-catalytic functions with PROTACs - PIM kinase as an example.利用PROTACs对抗通过非催化功能促进肿瘤发生的激酶——以PIM激酶为例。
Expert Opin Ther Targets. 2025 Apr-May;29(4-5):189-191. doi: 10.1080/14728222.2025.2500418. Epub 2025 May 4.
2
PIM1 targeted degradation prevents the emergence of chemoresistance in prostate cancer.PIM1 靶向降解可防止前列腺癌产生耐药性。
Cell Chem Biol. 2024 Feb 15;31(2):326-337.e11. doi: 10.1016/j.chembiol.2023.10.023. Epub 2023 Nov 27.
3
A review on structure-function mechanism and signaling pathway of serine/threonine protein PIM kinases as a therapeutic target.丝氨酸/苏氨酸蛋白PIM激酶作为治疗靶点的结构-功能机制及信号通路综述
Int J Biol Macromol. 2024 Jun;270(Pt 1):132030. doi: 10.1016/j.ijbiomac.2024.132030. Epub 2024 May 3.
4
Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.吉特替尼弹头 PROTACs 通过靶向降解扩展到 ALK 融合蛋白。
Bioorg Chem. 2024 Apr;145:107204. doi: 10.1016/j.bioorg.2024.107204. Epub 2024 Feb 14.
5
Identification of novel and potent PROTACs targeting FAK for non-small cell lung cancer: Design, synthesis, and biological study.针对非小细胞肺癌的新型强效 FA K 靶向 PROTAC 的鉴定：设计、合成与生物学研究。
Eur J Med Chem. 2022 Jul 5;237:114373. doi: 10.1016/j.ejmech.2022.114373. Epub 2022 Apr 23.
6
Light-induced control of protein destruction by opto-PROTAC.光诱导的光控 PROTAC 蛋白降解
Sci Adv. 2020 Feb 21;6(8):eaay5154. doi: 10.1126/sciadv.aay5154. eCollection 2020 Feb.
7
Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels.Pim激酶通过在转录和转录后水平上磷酸化并下调p27Kip1来促进细胞周期进程。
Cancer Res. 2008 Jul 1;68(13):5076-85. doi: 10.1158/0008-5472.CAN-08-0634.
8
Pim kinase isoforms: devils defending cancer cells from therapeutic and immune attacks.Pim激酶亚型：保护癌细胞免受治疗和免疫攻击的“恶魔”
Apoptosis. 2016 Nov;21(11):1203-1213. doi: 10.1007/s10495-016-1289-3.
9
Feedback Loop Regulation between Pim Kinases and Tax Keeps Human T-Cell Leukemia Virus Type 1 Viral Replication in Check.反馈环调节 Pim 激酶和 Tax 维持人 T 细胞白血病病毒 1 型病毒复制。
J Virol. 2022 Feb 9;96(3):e0196021. doi: 10.1128/JVI.01960-21. Epub 2021 Nov 24.
10
PIM Kinases in Multiple Myeloma.多发性骨髓瘤中的PIM激酶
Cancers (Basel). 2021 Aug 26;13(17):4304. doi: 10.3390/cancers13174304.
本文引用的文献
1
Targeting c-MYC and gain-of-function p53 through inhibition or degradation of the kinase LZK suppresses the growth of HNSCC tumors.通过抑制或降解激酶LZK靶向c-MYC和功能获得性p53可抑制头颈部鳞状细胞癌肿瘤的生长。
Sci Signal. 2025 Feb 11;18(873):eado2857. doi: 10.1126/scisignal.ado2857.
2
PROTAC protein degraders to drug the undruggable enter phase 3 trials.用于攻克不可成药靶点的PROTAC蛋白降解剂进入3期试验。
Nat Med. 2024 Nov;30(11):3030-3031. doi: 10.1038/d41591-024-00072-8.
3
PIM1 targeted degradation prevents the emergence of chemoresistance in prostate cancer.PIM1 靶向降解可防止前列腺癌产生耐药性。
Cell Chem Biol. 2024 Feb 15;31(2):326-337.e11. doi: 10.1016/j.chembiol.2023.10.023. Epub 2023 Nov 27.
4
Targeting Pim kinases in hematological cancers: molecular and clinical review.靶向血液系统恶性肿瘤的 Pim 激酶：分子与临床综述。
Mol Cancer. 2023 Jan 25;22(1):18. doi: 10.1186/s12943-023-01721-1.
5
Stabilization of PIM Kinases in Hypoxia Is Mediated by the Deubiquitinase USP28.缺氧条件下 PIM 激酶的稳定是由去泛素化酶 USP28 介导的。
Cells. 2022 Mar 16;11(6):1006. doi: 10.3390/cells11061006.
6
Degraders: The Ultimate Weapon Against Amplified Driver Kinases in Cancer.降解剂：癌症中扩增驱动激酶的终极武器。
Mol Pharmacol. 2022 Apr;101(4):191-200. doi: 10.1124/molpharm.121.000306. Epub 2022 Feb 3.
7
Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.在弥漫性大 B 细胞淋巴瘤中抑制 PIM 激酶可靶向 MYC 转录程序，并增强抗 CD20 抗体的疗效。
Cancer Res. 2021 Dec 1;81(23):6029-6043. doi: 10.1158/0008-5472.CAN-21-1023. Epub 2021 Oct 8.
8
Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer.协同 PIM 激酶和蛋白酶体抑制作为过表达 MYC 的三阴性乳腺癌的治疗策略。
Cell Chem Biol. 2022 Mar 17;29(3):358-372.e5. doi: 10.1016/j.chembiol.2021.08.011. Epub 2021 Sep 14.
9
Mutant-selective degradation by BRAF-targeting PROTACs.BRAF 靶向 PROTAC 介导的突变体选择性降解。
Nat Commun. 2021 Feb 10;12(1):920. doi: 10.1038/s41467-021-21159-7.
10
Targeting PIM Kinases to Overcome Therapeutic Resistance in Cancer.靶向 PIM 激酶以克服癌症治疗耐药性。
Mol Cancer Ther. 2021 Jan;20(1):3-10. doi: 10.1158/1535-7163.MCT-20-0535. Epub 2020 Dec 10.
Zotero 插件